Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

Update of antibody-drug conjugates for hematological malignancies

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

Targeting cancer with antibody-drug conjugates: Promises and challenges

Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review)

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

Emerging antibody-drug conjugates for treating lymphoid malignancies

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Antibody–drug conjugates come of age in oncology

Unlocking the potential of antibody–drug conjugates for cancer therapy

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Exploring the next generation of antibody–drug conjugates

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Potential of antibody–drug conjugates (ADCs) for cancer therapy

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads

Optimizing the safety of antibody–drug conjugates for patients with solid tumours